Serum Interleukin 23 in Psoriatic Arthritis Patients: Relation to
                    disease activity, physical function and health related quality of
                    life

Noha Abdelhalim Elsawy; Abdelmoniem Helal; Mohamed El Shafei; Neveen Lewis Mikhael; Nesrin Ahmed Aboeladl

doi:10.1055/a-1059-9475

Aktuelle Rheumatologie, Inhaltsverzeichnis

Aktuelle Rheumatologie 2020; 45(05): 460-466
DOI: 10.1055/a-1059-9475

Original Article

Serum Interleukin 23 in Psoriatic Arthritis Patients: Relation to disease activity, physical function and health related quality of life

Serum-Interleukin-23 bei Patienten mit Psoriasis-Arthritis: Zusammenhang mit Krankheitsaktivität, körperlicher Funktion und gesundheitsbezogener Lebensqualität

Autoren

Noha Abdelhalim Elsawy

¹Physical medicine, Rheumatology and Rehabilitation Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Abdelmoniem Helal

¹Physical medicine, Rheumatology and Rehabilitation Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Mohamed El Shafei

²Radiodiagnosis Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Neveen Lewis Mikhael

³Clinical and Chemical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Nesrin Ahmed Aboeladl

⁴Rheumatology and Rehabilitation Department, Faculty of Medicine, Helwan University, Cairo, Egypt

Abstract

Objective To assess interleukin 23 (IL-23) levels in the sera of psoriatic arthritis (PsA) patients and to determine the relationship of IL-23 with different disease activity indices, physical function and quality of life (QoL).

Methods Fifty PsA patients and 46 matched healthy controls were included in this study. Data including a detailed history, a thorough clinical examination, skin severity based on the Psoriasis Area and Severity Index (PASI), the Disease Activity index for Psoriatic Arthritis (DAPSA) and the Composite Psoriatic Disease Activity Index (CPDAI) were obtained for all patients. Physical function was assessed by the Health Assessment Questionnaire Disability Index (HAQ-DI) and health-related QoL was assessed using the Short Form Health Survey (SF-36), Psoriatic Arthritis Quality of Life (PsAQoL) and the Dermatology Life Quality Index (DLQI) were also assessed. Serum IL-23 levels were measured in the studied groups.

Results The study included 23(46%) females and 27 (54%) males with a mean age of 42.78±12.33 years. The mean serum IL-23 level was significantly higher in PsA patients (50.89±13.86 pg/ml) than in controls (43.88±6.34 pg/ml) (p=0.006). There were significant correlations between serum IL-23 levels and different grades of DAPSA activity (p=0.007) and PASI (p=0.015). No significant correlations could be detected between serum IL-23 levels and (HAQ-DI, DLQI, SF-36 or PsAQoL). CPDAI and DAPSA were significantly correlated with DLQI, SF-36 and PsAQoL.

Conclusion IL-23 is a useful biomarker for identifying joint activity or skin severity but not QoL or physical function.

Zusammenfassung

Ziel Beurteilung des Serumspiegels von Interleukin-23 (IL-23) bei Patienten mit Psoriasis-Arthritis (PsA) und Ermittlung des Zusammenhangs zwischen IL-23 und verschiedenen Krankheitsaktivitätsindizes, körperlicher Funktion und Lebensqualität (QoL).

Methoden In diese Studie wurden 50 PsA-Patienten und 46 vergleichbare gesunde Kontrollprobanden aufgenommen. Die bei allen Patienten durchgeführte Datenerhebung umfasste eine detaillierte Anamnese, eine sorgfältige klinische Untersuchung, Ermittlung des Schweregrads der Hautläsionen basierend auf dem Psoriasis Area and Severity Index (PASI), dem Disease Activity Index for Psoriatic Arthritis (DAPSA) und dem Composite Psoriatic Disease Activity Index (CPDAI). Die körperliche Funktion wurde anhand des Health Assessment Questionnaire Disability Index (HAQ-DI) und die gesundheitsbezogene Lebensqualität anhand des Short Form Health Survey (SF-36), des Psoriatic Arthritis Quality of Life (PsAQoL) und des Dermatology Life Quality Index (DLQI) beurteilt. In den untersuchten Gruppen wurden die Serumspiegel von IL-23 gemessen.

Ergebnisse Die Studie umfasste 23 (46 %) Frauen und 27 (54 %) Männer mit einem mittleren Alter von 42,78±12,33 Jahren. Der mittlere Serumspiegel von IL-23 war bei den PsA-Patienten (50,89±13,86 pg/ml) signifikant höher als bei den Kontrollprobanden (43,88±6,34 pg/ml) (p=0,006). Die Serumspiegel von IL-23 korrelierten signifikant mit verschiedenen Graden der mithilfe des DAPSA (p=0,007) und des PASI (p=0,015) ermittelten Krankheitsaktivität. Keine signifikanten Korrelationen fanden sich zwischen den IL-23-Serumspiegeln und HAQ-DI, DLQI, SF-36 oder PsAQoL. CPDAI und DAPSA korrelierten signifikant mit DLQI, SF-36 und PsAQoL.

Schlussfolgerung IL-23 ist ein nützlicher Biomarker zur Identifikation der Krankheitsaktivität oder des Schweregrads von Hautläsionen, aber nicht zur Ermittlung von Lebensqualität oder körperlicher Funktion.

Key words

PsA - IL-23 - DAPSA - SF-36 - PsAQoL

Schlüsselwörter

PsA - IL-23 - DAPSA - SF-36 - PsAQoL

Volltext

Referenzen

References
1 Farrag DA, Asaad MK, Ghobrial CK. Evaluation of IL-34 in psoriasis and psoriatic arthritis patients: Correlation with disease activity and severity. Egypt Rheumatol 2017; 39: 25-31
2 McInnes IB, Sieper J, Braun J. et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73: 349-356
3 Piaserico S, Gisondi P, Amerio P. et al. Validation and field performance of the Italian version of the psoriatic arthritis screening and evaluation (PASE) questionnaire. Acta Derm Venereol 2016; 96: 96-101
4 Gheita TA, Azkalany GS, Kenawy SA. et al. Bone scintigraphy in axial seronegative spondyloarthritis patients: role in detection of subclinical peripheral arthritis and disease activity. Int J Rheum Dis 2015; 18: 553-559
5 Mumtaz A, Gallagher P, Kirby B. et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011; 70: 272-277
6 Orbai AM, De Wit M, Mease P. et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 2017; 76: 673-680
7 Rudwaleit Mv, Van Der Heijde D, Landewé R. et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25-31
8 van der Heijde D, Sieper J, Maksymowych WP. et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-908
9 Aletaha D, Alasti F, Smolen J. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis 2017; 76: 418-421
10 Schoels MM, Aletaha D, Alasti F. et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016; 75: 811-818
11 Mease P, Antoni C, Gladman D. et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. 02) ii49-ii54
12 Alsheikh MM, El-Shafey AM, Gawish HH. et al. Serum interleukin-23 level in rheumatoid arthritis patients: Relation to disease activity and severity. Egypt Rheumatol 2018; 41: 99-103
13 Reinhardt A, Yevsa T, Worbs T. et al. Interleukin-23–dependent γ/δ T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. Arthritis Rheumatol 2016; 68: 2476-2486
14 Selim ZI, Rashad SM, Abdelaziz MM. et al. Interleukin-34 in the Serum and Synovial Fluid of Rheumatoid Arthritis Patients: Relation to Disease Activity and Radiographic Damage. Aktuelle Rheumatol 2019; 58: 65-70
15 Hadidi HE, Bahaa G, Gheita T. et al. Involvement of IL-23 in psoriasis and psoriatic arthritis patients: possible role in pathogenesis. J Egypt wom Dermatol soc 2008; 5: 70-76
16 Gómez-García F, Epstein D, Isla-Tejera B. et al. Short-term efficacy and safety of new biological agents targeting the interleukin-23–T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Br J Dermatol 2017; 176: 594-603
17 Raychaudhuri SP, Raychaudhuri SK. IL-23/IL-17 axis in spondyloarthritis-bench to bedside. Clin Rheumatol 2016; 35: 1437-1441
18 McKenna SP, Doward LC, Whalley D. et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004; 63: 162-169
19 Taylor W, Gladman D, Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673
20 Turconi G, Guarcello M, Maccarini L. et al. BMI values and other anthropometric and functional measurements as predictors of obesity in a selected group of adolescents. Eur J Nutr 2006; 45: 136-143
21 Faustini F, Simon D, Oliveira I. et al. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis. Ann Rheum Dis 2016; 75: 2068-2074
22 Heuft-Dorenbosch L, Spoorenberg A, Van Tubergen A. et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62: 127-132
23 Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 2011; 63 (Suppl 11): S64-S85
24 Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28: 333-337
25 Ibrahim SE, Helmi A, Yousef TM. et al. Association of asymptomatic hyperuricemia and endothelial dysfunction in psoriatic arthritis. Egypt Rheumatol 2012; 34: 83-89
26 Ibrahim SE, Morshedy NA, Farouk N. et al. Anti-carbamylated protein antibodies in psoriatic arthritis patients: relation to disease activity, severity and ultrasonographic scores. Egypt Rheumatol 2018; 40: 17-21
27 Helliwell PS, FitzGerald O, Fransen J. et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013; 72: 986-991
28 Michelsen B, Diamantopoulos AP, Hammer HB. et al. Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. Ann Rheum Dis 2016; 75: 2108-2113
29 Poole CD, Conway P, Currie CJ. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology (Oxford) 2009; 48: 78-82
30 Bogliolo L, Alpini C, Caporali R. et al. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005; 32: 511-515
31 ThermoFisher SCIENTIFIC. IL-23 Human ELISA Kit. Available from https://www.thermofisher.com/elisa/product/IL-23-Human-ELISA-Kit/BMS2023-3 [Accessed in: May, 2019].
32 Abdelsalam A, Tharwat S, Almauty MA. et al. Demographic, clinical and radiological characteristics of seronegative spondyloarthritis Egyptian patients: a rheumatology clinic experience in Mansoura. Egypt Rheumatol 2017; 39: 109-114
33 Hukuda S, Minami M, Saito T. et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001; 28: 554-559
34 Trontzas P, Andrianakos A, Miyakis S. et al. Seronegative spondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study. Clin Rheumatol 2005; 24: 583-589
35 Kavanaugh A, Puig L, Gottlieb AB. et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis 2016; 75: 1984-1988
36 Gottlieb A, Menter A, Mendelsohn A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009; 373: 633-640
37 Przepiera-Bedzak H, Fischer K, Brzosko M. Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. Mediators Inflamm 2015; 2015: 785705
38 Chen WS, Chang YS, Lin KC. et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc 2012; 75: 303-308
39 Gheita TA, El G, El-Fishawy HS. et al. Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results. Clin Rheumatol 2014; 33: 713-717
40 Wendling D, Cedoz JP, Racadot E. Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients. Clin Rheumatol 2009; 28: 187-190
41 Elghandour TM, Youssef Sel S, Aly DG. et al. Effect of Narrow Band Ultraviolet B Therapy versus Methotrexate on Serum Levels of Interleukin-17 and Interleukin-23 in Egyptian Patients with Severe Psoriasis. Dermatol Res Pract 2013; 2013: 618269
42 Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 2012; 11: 159-168
43 Iannone F, Santo L, Bucci R. et al. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). Clin Rheumatol 2018; 37: 667-675
44 Melis L, Vandooren B, Kruithof E. et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010; 69: 618-623
45 Mrabet D, Laadhar L, Sahli H. et al. Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study. Rheumatol Int 2013; 33: 265-266
46 Kerschbaumer A, Fenzl KH, Erlacher L. et al. An overview of psoriatic arthritis – epidemiology, clinical features, pathophysiology and novel treatment targets. Wiener klinische Wochenschrift 2016; 128: 791-795
47 McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet 1998; 352: 1137-1140
48 Coimbra S, Oliveira H, Reis F. et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol 2010; 163: 1282-1290
49 Sofen H, Smith S, Matheson RT. et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014; 133: 1032-1040
50 Kerschbaumer A, Smolen JS, Aletaha D. Disease activity assessment in patients with psoriatic arthritis. Best Pract Res Clin Rheumatol 2018; 32: 401-414
51 Borman P, Toy GG, Babaoğlu S. et al. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol 2007; 26: 330-334
52 Husted JA, Gladman DD, Farewell VT. et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001; 45: 151-158
53 Husted J, Gladman D, Long J. et al. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995; 13: 439-443
54 Taylor WJ. Assessment of outcome in psoriatic arthritis. Curr Opin Rheumatol 2004; 16: 350-356
55 Tezel N, Yilmaz Tasdelen O, Bodur H. et al. Is the health-related quality of life and functional status of patients with psoriatic arthritis worse than that of patients with psoriasis alone?. Int J Rheum Dis 2015; 18: 63-69
56 Rosen CF, Mussani F, Chandran V. et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford) 2012; 51: 571-576
57 FitzGerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009; 11: 214
58 Chimenti MS, Triggianese P, De Martino E. et al. An update on pathogenesis of psoriatic arthritis and potential therapeutic targets. Expert Rev Clin Immunol 2019; 1-14
59 Arican O, Aral M, Sasmaz S. et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005: 273-279
60 Duruöz M, Uçar Ü, Guvenç Y. et al. AB0117 Evaluation of serum levels of interleukin (il)-17a, il-17b, il-17c, il-17f and il-23 levels in psoriatic arthritis. Ann Rheum Dis 2013; 72 (Suppl. 03) A821-A821
61 Blauvelt A, Papp KA, Griffiths CE. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405-417